Biothera Announces Three Presentations at Upcoming American Association for Cancer Research Annual Meeting

EAGAN, MN — March 27, 2017 — Biothera Pharmaceuticals Inc. announced today that it will present three scientific posters at the American Association for Cancer Research (AACR) Annual Meeting April 1-5 in Washington, D.C. One poster was selected for the late-breaking session that highlights the newest and most exciting research.

Poster Presentations:

Session Date & Time:  Monday, April 3, 8:00 AM – 12:00 PM Eastern Time
Topic Track:  Immunology
Session:  Adaptive Immunity to Cancer
Presentation Title: A novel tumor vaccine platform: direct conjugation of antigens to the β-glucan PAMP Imprime PGG enhances antigen presentation and T cell priming
Session Location: Poster Section 29
Poster Board Number: 22
Abstract #:  1703
Session Date & Time:  Tuesday, April 4, 8:00 AM – 12:00 PM Eastern Time
Topic Track:  Immunology
Session:  Late-Breaking Research: Immunology
Presentation Title: Imprime PGG modulates immunosuppressive myeloid components of the tumor microenvironment and drives enhanced antitumor efficacy in combination with checkpoint inhibitor therapies
Session Location: Poster Section 35
Poster Board Number: 22
Abstract #:  LB-199
Session Date & Time:  Tuesday, April 4, 8:00 AM – 12:00 PM Eastern Time
Topic Track:  Immunology
Session:  Inflammation in the Tumor Microenvironment
Presentation Title: Imprime PGG, a novel innate immune therapeutic in phase 2 clinical development, induces mobilization of monocytes and focalized recruitment of innate immune cells to tumor sites
Session Location: Poster Section 28
Poster Board #: 1
Abstract #:  3688


About Biothera Pharmaceuticals, Inc.
Biothera Pharmaceuticals is a privately held biotechnology company developing Imprime PGG, a Phase 2 cancer immunotherapy that enhances the efficacy of anti-cancer immune response in combination with immune checkpoint inhibitor, tumor-targeting and anti-angiogenesis antibodies.  Biothera Pharmaceuticals has clinical research agreements with Merck to evaluate Imprime PGG and KEYTRUDA® in Phase 2 studies in advanced melanoma, metastatic triple negative breast cancer, and head and neck squamous cell cancer. This therapeutic combination also is the focus of a Big Ten Cancer Research Consortium Phase 1b/2 trial in patients with non-small cell lung cancer. Imprime PGG has been well-tolerated and has established proof of concept in trials with more than 400 subjects.

KEYTRUDA® is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.

Contact:
David Walsh
Communications
Biothera Pharmaceuticals, Inc.
651-256-4606
dwalsh@biothera.com

Share

David Walsh

Leave a Reply

Your email address will not be published. Required fields are marked *